• Discuss the advantages and disadvantages of the new oral anticoagulants (NOAC) compared to warfarin • Review the pharmacology and indications of each agent • Compare the efficacy and safety of agents in clinical trials • List agents in the pipeline for reversal of the new oral anticoagulants 2 New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Family Medicine Spring Symposium April 10, 2015 Have you prescribed any of the following new oral anticoagulants? ( Transitioning from NOAC to Warfarin • Dabigatran -CrCl > 50mL/min: initiate warfarin 3 days before D/C dabigatran -CrCl 30 50mL/min: initiate warfarin 2 days before D/C dabigatran -CrCl 15 30mL/min: initiate warfarin 1 day before D/C dabigatran -CrCl <15mL/min: no recommendation available
• Rivaroxaban and Apixaban -Discontinue NOAC, start parenteral antcoagulation plus warfarin, D/C parenteral anticoagulant when warfarin INR therapeutic -OR may initiate warfarin 3 5 days before D/C rivaroxaban or apixaban • Edoxaban -Decrease dose 50%, start warfarin and continue edoxaban until INR >2 -OR may D/C edoxaban and use parenteral anticoagulant to transition Family Medicine Spring Symposium April 10, 2015
